Phaseline

Targets › MMAE

MMAE: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology.

Open in Phaseline: the race on MMAE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Zhejiang Teruisi PharmaceuticalTRS005
Anti-CD20 monoclonal antibody-MMAE antibody-drug conjugate
CD20, MMAEPhase 1CD20-positive B-cell Non-Hodgkin Lymphoma–

Conditions

CD20-positive B-cell Non-Hodgkin Lymphoma (1)

Modalities

antibody (1)

Companies

Zhejiang Teruisi Pharmaceutical (1)

Related targets

CD20 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.